KalVista Pharmaceuticals, Inc. (4XC1.F)
Frankfurt · EUR · Healthcare · Biotechnology
€22.73 (+0.00%) as of
Key statistics
- Market cap
- 1.21B
- Forward P/E
- -6.21
- EPS (TTM)
- -3.40
- 52-week range
- 9.00 – 23.26
- Beta
- -0.11
- Revenue (TTM)
- 114.48M
- Profit margin
- -118.74%
- Volume
- 300.00
About KalVista Pharmaceuticals, Inc.
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Framingham, MA, United States
- Employees
- 275
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.